RGL2

Across TCGA pan-cancer cohorts, RGL2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RGL2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where RGL2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RGL2 is over-expressed in tumor, although a few such as COAD and LSCC show the opposite, repressed pattern.

COAD, CCRCC, and LSCC are the cancer types where RGL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RGL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	II,III,IV	−0.772	<.001	10	view →
CCRCC	Female	All	+0.273	<.001	10	view →
LSCC	Male	All	−0.831	<.001	9	view →
LUAD	Female	III,IV	−0.580	<.001	9	view →
HNSC	Male	All	−0.453	<.001	8	view →
PDAC	Female	III,IV	−0.370	.005	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RGL2–COAD

Open the COAD breakdown →